## Jerome Robert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6883568/publications.pdf

Version: 2024-02-01

173 papers

9,648 citations

44069 48 h-index 94 g-index

201 all docs

201 docs citations

times ranked

201

8594 citing authors

#	Article	IF	CITATIONS
1	Outcomes of Primary and Catheter-related Bacteremia. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 1584-1590.	5.6	833
2	Global Trends in Resistance to Antituberculosis Drugs. New England Journal of Medicine, 2001, 344, 1294-1303.	27.0	567
3	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, The, 2018, 392, 821-834.	13.7	452
4	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. PLoS Medicine, 2012, 9, e1001300.	8.4	430
5	Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. European Respiratory Journal, 2013, 42, 156-168.	6.7	346
6	Sixty-three Cases of Mycobacterium marinum Infection. Archives of Internal Medicine, 2002, 162, 1746.	3.8	324
7	Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug) Tj ETQq1 1 0.784	314 rgBT	Oyerlock 10
8	Surveillance for control of antimicrobial resistance. Lancet Infectious Diseases, The, 2018, 18, e99-e106.	9.1	235
9	Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. European Respiratory Journal, 2013, 42, 169-179.	6.7	226
10	The Influence of the Composition of the Nursing Staff on Primary Bloodstream Infection Rates in a Surgical Intensive Care Unit. Infection Control and Hospital Epidemiology, 2000, 21, 12-17.	1.8	219
11	Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific) Tj ETQq1 1 0.784	314 rgBT <sub>1.8</sub>	Oyerlock 10
12	Nebulized Ceftazidime and Amikacin in Ventilator-associated Pneumonia Caused by <i>Pseudomonas aeruginosa</i> . American Journal of Respiratory and Critical Care Medicine, 2011, 184, 106-115.	5.6	183
13	Efficacy of High-dose Nebulized Colistin in Ventilator-associated Pneumonia Caused by Multidrug-resistant <i>Pseudomonas aeruginosa</i> Â and <i>Acinetobacter baumannii</i> Â. Anesthesiology, 2012, 117, 1335-1347.	2.5	177
14	Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact. Diabetic Medicine, 2004, 21, 710-715.	2.3	167
15	Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort. Clinical Infectious Diseases, 2015, 60, 188-194.	5.8	165
16	Curbing Methicillin-Resistant Staphylococcus aureus in 38 French Hospitals Through a 15-Year Institutional Control Program. Archives of Internal Medicine, 2010, 170, 552.	3.8	138
17	Comparison of Nine Phenotypic Methods for Detection of Extended-Spectrum $\hat{l}^2$ -Lactamase Production by Enterobacteriaceae. Journal of Clinical Microbiology, 2011, 49, 1048-1057.	3.9	123
18	A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study. Lancet Infectious Diseases, The, 2018, 18, 431-440.	9.1	121

#	Article	IF	CITATIONS
19	Type II Topoisomerase Mutations in Ciprofloxacin-Resistant Strains of <i>Pseudomonas aeruginosa</i> Antimicrobial Agents and Chemotherapy, 1999, 43, 62-66.	3.2	120
20	Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis. Clinical Infectious Diseases, 2014, 59, 1364-1374.	5.8	116
21	Elaboration of a consensual definition of de-escalation allowing a ranking of $\hat{l}^2$ -lactams. Clinical Microbiology and Infection, 2015, 21, 649.e1-649.e10.	6.0	112
22	Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. European Respiratory Journal, 2017, 49, 1601799.	6.7	112
23	Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study. Annals of Intensive Care, 2020, 10, 158.	4.6	108
24	Nationwide survey of extended-spectrum $\hat{l}^2$ -lactamase-producing Enterobacteriaceae in the French community setting. Journal of Antimicrobial Chemotherapy, 2009, 63, 1205-1214.	3.0	103
25	In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrobial Agents and Chemotherapy, 2006, 50, 1921-1926.	3.2	100
26	Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. International Journal of Tuberculosis and Lung Disease, 2015, 19, 969-978.	1.2	99
27	Bacillus cereus, a serious cause of nosocomial infections: Epidemiologic and genetic survey. PLoS ONE, 2018, 13, e0194346.	2.5	99
28	Lung Tissue Concentrations of Nebulized Amikacin during Mechanical Ventilation in Piglets with Healthy Lungs. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 171-175.	5.6	88
29	Aerosolized Antibiotics for Ventilator-associated Pneumonia. Anesthesiology, 2012, 117, 1364-1380.	2.5	87
30	Rapid emergence of <i>Mycobacterium tuberculosis</i> bedaquiline resistance: lessons to avoid repeating past errors. European Respiratory Journal, 2017, 49, 1601719.	6.7	86
31	Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983–2002. Journal of Antimicrobial Chemotherapy, 2006, 57, 506-510.	3.0	83
32	Comparison of silver-impregnated with standard multi-lumen central venous catheters in critically ill patients*. Critical Care Medicine, 2007, 35, 1032-1039.	0.9	80
33	Bactericidal Activity of Rifampin-Amikacin against Mycobacterium ulcerans in Mice. Antimicrobial Agents and Chemotherapy, 2002, 46, 3193-3196.	3.2	78
34	Outcome of Multi-drug-resistant Tuberculosis in France. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 587-593.	5.6	77
35	Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1029-1031.	5.6	71
36	Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. Lancet, The, 2020, 395, 1259-1267.	13.7	71

#	Article	IF	CITATIONS
37	Activities of Several Antimicrobials against Mycobacterium ulcerans Infection in Mice. Antimicrobial Agents and Chemotherapy, 2000, 44, 2367-2372.	3.2	69
38	Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. Emerging Infectious Diseases, 2019, 25, 936-943.	4.3	68
39	Activities of New Macrolides and Fluoroquinolones against Mycobacterium ulcerans Infection in Mice. Antimicrobial Agents and Chemotherapy, 2001, 45, 3109-3112.	3.2	66
40	Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. Clinical Infectious Diseases, 2016, 62, 887-895.	5.8	64
41	Carriage of Methicillin-Resistant Staphylococcus aureus in Home Care Settings. Archives of Internal Medicine, 2009, 169, 1372.	3.8	63
42	Point prevalence survey of antibiotic use in French hospitals in 2009. Journal of Antimicrobial Chemotherapy, 2012, 67, 1020-1026.	3.0	59
43	Orally Administered Combined Regimens for Treatment of <i>Mycobacterium ulcerans</i> Infection in Mice. Antimicrobial Agents and Chemotherapy, 2007, 51, 3737-3739.	3.2	57
44	Occurrence of qnrA-positive clinical isolates in French teaching hospitals during 2002–2005. Clinical Microbiology and Infection, 2006, 12, 1013-1020.	6.0	56
45	Nationwide Investigation of Extended-Spectrum $\hat{l}^2$ -Lactamases, Metallo- $\hat{l}^2$ -Lactamases, and Extended-Spectrum Oxacillinases Produced by Ceftazidime-Resistant <1>Pseudomonas aeruginosaStrains in France. Antimicrobial Agents and Chemotherapy, 2010, 54, 3512-3515.	3.2	56
46	Incidence rates of carbapenemase-producing Enterobacteriaceae clinical isolates in France: a prospective nationwide study in 2011-12. Journal of Antimicrobial Chemotherapy, 2014, 69, 2706-2712.	3.0	51
47	Molecular epidemiology of OXA-48-producing Klebsiella pneumoniae in France. Clinical Microbiology and Infection, 2014, 20, O1121-O1123.	6.0	51
48	Pharmacodynamics of antibiotics in fibrin clots. Journal of Antimicrobial Chemotherapy, 1993, 31, 113-136.	3.0	49
49	Nosocomial infections and hospital mortality: a multicentre epidemiological study. Journal of Hospital Infection, 2004, 58, 268-275.	2.9	49
50	High Rate of Multidrug-Resistant Gram-Negative Bacilli Carriage and Infection in Hospitalized Returning Travelers: a Cross-Sectional Cohort Study. Journal of Travel Medicine, 2015, 22, 292-299.	3.0	48
51	Performance of the New Version (v2.0) of the GenoType MTBDR <i>sl</i> Test for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant Mycobacterium tuberculosis Complex Strains. Journal of Clinical Microbiology, 2016, 54, 1573-1580.	3.9	46
52	Three-year survey of community-acquired methicillin-resistant Staphylococcus aureus producing Panton-Valentine leukocidin in a French university hospital. Journal of Hospital Infection, 2005, 61, 321-329.	2.9	45
53	Panton-Valentine Leukocidin-Positive and Toxic Shock Syndrome Toxin 1-Positive Methicillin-Resistant <i>Staphylococcus aureus </i> : a French Multicenter Prospective Study in 2008. Antimicrobial Agents and Chemotherapy, 2011, 55, 1734-1739.	3.2	45
54	Methicillin-resistant Staphylococcus aureus producing Panton–Valentine leukocidin in a retrospective case series from 12 French hospital laboratories, 2000–2003. Clinical Microbiology and Infection, 2005, 11, 585-587.	6.0	44

#	Article	IF	CITATIONS
55	Long-term control of carbapenemase-producing Enterobacteriaceae at the scale of a large French multihospital institution: a nine-year experience, France, 2004 to 2012. Eurosurveillance, 2014, 19, .	7.0	44
56	Type II topoisomerase mutations in clinical isolates of Enterobacter cloacae and other enterobacterial species harbouring the qnrA gene. International Journal of Antimicrobial Agents, 2007, 29, 402-409.	2.5	43
57	Extended-spectrum $\hat{I}^2$ -lactamases in long-term-care facilities. Clinical Microbiology and Infection, 2008, 14, 111-116.	6.0	43
58	Prevalence of extended-spectrum beta-lactamase producing Escherichia coli inÂcommunity-onset urinary tract infections in France in 2013. Journal of Infection, 2016, 72, 201-206.	3.3	42
59	Distinguishing Colonization From Infection With <i>Staphylococcus aureus</i> in Diabetic Foot Ulcers With Miniaturized Oligonucleotide Arrays. Diabetes Care, 2012, 35, 617-623.	8.6	41
60	Multidrug-resistant tuberculosis: eight years of surveillance in France. European Respiratory Journal, 2003, 22, 833-837.	6.7	40
61	A surge of MDR and XDR tuberculosis in France among patients born in the Former Soviet Union. Eurosurveillance, 2013, 18, 20555.	<b>7.</b> 0	37
62	Patient's Origin and Lifestyle Associated with CTX-M-Producing Escherichia coli: A Case-Control-Control Study. PLoS ONE, 2012, 7, e30498.	2.5	36
63	Pacemaker Endocarditis Due to Candida albicans: Case Report and Review. Clinical Infectious Diseases, 1997, 25, 1359-1362.	5.8	35
64	Twenty years of antimicrobial resistance control programme in a regional multi hospital institution, with focus on emerging bacteria (VRE and CPE). Antimicrobial Resistance and Infection Control, 2012, 1, 9.	4.1	35
65	Molecular Diagnosis of Fluoroquinolone Resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2015, 59, 1519-1524.	3.2	35
66	Comparison of methods available for identification of Mycobacterium chimaera. Clinical Microbiology and Infection, 2018, 24, 409-413.	6.0	34
67	Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease. European Respiratory Journal, 2005, 26, 1092-1096.	6.7	33
68	Preventing Central Venous Catheter-Associated Primary Bloodstream Infections: Characteristics of Practices Among Hospitals Participating in the Evaluation of Processes and Indicators in Infection Control (EPIC) Study. Infection Control and Hospital Epidemiology, 2003, 24, 926-935.	1.8	32
69	Bactericidal and Sterilizing Activities of Several Orally Administered Combined Regimens against <i>Mycobacterium ulcerans</i> in Mice. Antimicrobial Agents and Chemotherapy, 2008, 52, 1912-1916.	3.2	31
70	Risk factors for carbapenem-resistant Enterobacteriaceae infections: a French case-control-control study. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 383-393.	2.9	31
71	Safety and efficacy of exposure to bedaquilineâ^'delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia. European Respiratory Journal, 2018, 51, 1702550.	6.7	30
72	Long-term control of vancomycin-resistant Enterococcus faecium at the scale of a large multihospital institution: a seven-year experience. Eurosurveillance, 2012, 17, .	7.0	30

#	Article	IF	Citations
73	Effect of Catheter-Lock Solutions on Catheter-Related Infection and Inflammatory Syndrome in Hemodialysis Patients: Heparin versus Citrate 46% versus Heparin/Gentamicin. Blood Purification, 2010, 29, 268-273.	1.8	29
74	A 10-year prospective surveillance of Mycobacterium tuberculosis drug resistance in France 1995 2004. European Respiratory Journal, 2007, 30, 937-944.	6.7	28
75	First report of the predominance of clonal complex 398 Staphylococcus aureus strains in osteomyelitis complicating diabetic foot ulcers: a national French study. Clinical Microbiology and Infection, 2014, 20, O274-O277.	6.0	28
76	Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study. Microorganisms, 2021, 9, 282.	3.6	28
77	Surging bloodstream infections and antimicrobial resistance during the first wave of COVID–19: a study in a large multihospital institution in the Paris region. International Journal of Infectious Diseases, 2022, 114, 90-96.	3.3	28
78	Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016. BMC Infectious Diseases, 2018, 18, 331.	2.9	27
79	First multicenter study on multidrug resistant bacteria carriage in Chinese ICUs. BMC Infectious Diseases, 2015, 15, 358.	2.9	26
80	Multidrug and extensively drug-resistant tuberculosis. Médecine Et Maladies Infectieuses, 2017, 47, 3-10.	5.0	26
81	Detection of OXA-48-like carbapenemase genes by the Xpert® Carba-R test: room for improvement. International Journal of Antimicrobial Agents, 2015, 45, 441-442.	2.5	25
82	Efficacies of Clarithromycin Regimens against Mycobacterium xenopi in Mice. Antimicrobial Agents and Chemotherapy, 2001, 45, 3229-3230.	3.2	24
83	An intervention programme for the management of multidrug-resistant tuberculosis in France. International Journal of Antimicrobial Agents, 2007, 29, 434-439.	2.5	24
84	Increase in hospital-acquired bloodstream infections caused by extended spectrum $\hat{l}^2$ -lactamase-producing Escherichia coli in a large French teaching hospital. European Journal of Clinical Microbiology and Infectious Diseases, 2009, 28, 491-498.	2.9	24
85	Link Between Carbapenemaseâ€ProducingEnterobacteriaCarriage and Crossâ€Border Exchanges: Eight‥ear Surveillance in a Large French Multihospitals Institution. Journal of Travel Medicine, 2012, 19, 320-323.	3.0	24
86	Curing Mycobacterium ulcerans Infection in Mice with a Combination of Rifampin-Streptomycin or Rifampin-Amikacin. Antimicrobial Agents and Chemotherapy, 2007, 51, 645-650.	3.2	23
87	Carbapenem use in French hospitals: A nationwide survey at the patient level. International Journal of Antimicrobial Agents, 2015, 46, 707-712.	2.5	23
88	Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice. PLoS Neglected Tropical Diseases, 2016, 10, e0005066.	3.0	23
89	Rifampicin mono-resistant tuberculosis in France: a 2005–2010 retrospective cohort analysis. BMC Infectious Diseases, 2014, 14, 18.	2.9	22
90	Usefulness of point-of-care multiplex PCR to rapidly identify pathogens responsible for ventilator-associated pneumonia and their resistance to antibiotics: an observational study. Critical Care, 2020, 24, 378.	5.8	22

#	Article	IF	Citations
91	Management and outcome of bloodstream infections: a prospective survey in 121 French hospitals (SPA-BACT survey). Infection and Drug Resistance, 2018, Volume 11, 1359-1368.	2.7	21
92	Different Factors Associated with CTX-M-Producing ST131 and Non-ST131 Escherichia coli Clinical Isolates. PLoS ONE, 2013, 8, e72191.	2.5	20
93	Rapid Curbing of a Vancomycin-ResistantEnterococcus faeciumOutbreak in a Nephrology Department. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1559-1564.	4.5	19
94	Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?. European Respiratory Journal, 2016, 48, 582-585.	6.7	19
95	Neurological diseases of unknown etiology: Brain-biopsy diagnostic yields and safety. European Journal of Internal Medicine, 2020, 80, 78-85.	2.2	18
96	Molecular epidemiology of Pseudomonas aeruginosa isolated from infected ICU patients: a French multicenter 2012–2013 study. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 921-926.	2.9	18
97	Efficiency of different control measures for preventing carbapenemase-producing enterobacteria and glycopeptide-resistant Enterococcus faecium outbreaks: a 6-year prospective study in a French multihospital institution, January 2010 to December 2015. Eurosurveillance, 2018, 23, .	7.0	18
98	Impact of Hospital Care on Incidence of Bloodstream Infection: The Evaluation of Processes and Indicators in Infection Control Study. Emerging Infectious Diseases, 2001, 7, 193-196.	4.3	18
99	SUBACUTE POLYNEUROPATHY WITH ENCEPHALOPATHY IN AIDS WITH HUMAN CYTOMEGALOVIRUS PATHOGENICITY?. Lancet, The, 1986, 328, 1039.	13.7	17
100	Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital: 1992–98. Clinical Microbiology and Infection, 2001, 7, 553-561.	6.0	17
101	Impact of a 14-year screening programme on tuberculosis transmission among the homeless in Paris. International Journal of Tuberculosis and Lung Disease, 2012, 16, 649-655.	1.2	17
102	Implementation of isolation precautions: role of a targeted information flyer. Journal of Hospital Infection, 2006, 62, 163-165.	2.9	16
103	Incidence of tuberculous meningitis in France, 2000: a capture-recapture analysis. International Journal of Tuberculosis and Lung Disease, 2005, 9, 803-8.	1.2	16
104	Significant Difference in Drug Susceptibility Distribution between Mycobacterium avium and Mycobacterium intracellulare. Journal of Clinical Microbiology, 2014, 52, 4439-4440.	3.9	15
105	Antibiotic use and good practice in 314 French hospitals: The 2010 SPA2 prevalence study. Médecine Et Maladies Infectieuses, 2015, 45, 475-480.	5.0	14
106	A Comprehensive Evaluation of GeneLEAD VIII DNA Platform Combined to Deeplex Myc-TB® Assay to Detect in 8 Days Drug Resistance to 13 Antituberculous Drugs and Transmission of Mycobacterium tuberculosis Complex Directly From Clinical Samples. Frontiers in Cellular and Infection Microbiology, 2021, 11, 707244.	3.9	14
107	Surveillance of Mycobacterium tuberculosis drug resistance in France, 1995-1997. AZAY Mycobacteria Study Group. International Journal of Tuberculosis and Lung Disease, 2000, 4, 665-72.	1.2	14
108	Assessment of Organizational Measures to Prevent Nosocomial Tuberculosis in Health Facilities of 4 Sub-Saharan Countries in 2010. Infection Control and Hospital Epidemiology, 2013, 34, 190-194.	1.8	13

#	Article	IF	Citations
109	Pseudomonas aeruginosa in French hospitals between 2001 and 2011: back to susceptibility. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 1713-1717.	2.9	13
110	Comparison of US and non-US central venous catheter infection rates: Evaluation of processes and indicators in infection control study. American Journal of Infection Control, 2003, 31, 237-242.	2.3	12
111	Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis. PLoS ONE, 2016, 11, e0151724.	2.5	12
112	Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory. BMC Infectious Diseases, 2017, 17, 78.	2.9	12
113	Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study. International Journal of Tuberculosis and Lung Disease, 2018, 22, 54-59.	1.2	12
114	Preemptive Isolation to Prevent Methicillin-Resistant <i>Staphylococcus aureus</i> Cross-Transmission in Diabetic Foot. Diabetes Care, 2007, 30, 2341-2342.	8.6	11
115	XDR-tuberculosis in France: Community transmission due to non-compliance with isolation precautions. Médecine Et Maladies Infectieuses, 2016, 46, 52-55.	<b>5.</b> O	11
116	Molecular detection methods of resistance to antituberculosis drugs in Mycobacterium tuberculosis. Médecine Et Maladies Infectieuses, 2017, 47, 340-348.	5.0	11
117	Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician's perspective. Future Microbiology, 2020, 15, 779-799.	2.0	11
118	Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events. International Journal of Infectious Diseases, 2021, 107, 86-91.	3.3	11
119	An evaluation of data quality in a network for surveillance of Mycobacterium tuberculosis resistance to antituberculosis drugs in Ile-de-France region-2001–2002. European Journal of Epidemiology, 2006, 21, 783-785.	5.7	10
120	Assessing Primary and Secondary Resistance to Clarithromycin and Amikacin in Infections Due to Mycobacterium avium Complex. Antimicrobial Agents and Chemotherapy, 2015, 59, 7153-7155.	3.2	10
121	Multidisciplinary advisory teams to manage multidrug-resistant tuberculosis: the example of the French Consilium. International Journal of Tuberculosis and Lung Disease, 2019, 23, 1050-1054.	1.2	10
122	Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses. PLoS Neglected Tropical Diseases, 2020, 14, e0007857.	3.0	10
123	Impact of the BCG vaccination policy on tuberculous meningitis in children under 6 years in metropolitan France between 2000 and 2011. Eurosurveillance, 2015, 20, .	7.0	10
124	Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012â€'2020. Emerging Infectious Diseases, 2022, 28, 518-526.	4.3	10
125	Increase in primary drug resistance of Mycobacterium tuberculosis in younger birth cohorts in France. Journal of Infection, 2012, 64, 589-595.	3.3	9
126	In vivo Mycobacterium tuberculosisfluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests. Journal of Antimicrobial Chemotherapy, 2016, 71, 3465-3472.	3.0	9

#	Article	IF	Citations
127	Trends and prediction of antimicrobial susceptibility in urinary bacteria isolated in European emergency departments: the EuroUTI 2010-2016 Study. Journal of Antimicrobial Chemotherapy, 2019, 74, 3069-3076.	3.0	9
128	Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing. Frontiers in Microbiology, 2020, 11, 81.	3.5	9
129	Application of guidelines for aminoglycosides use in French hospitals in 2013–2014. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 1083-1090.	2.9	8
130	Trimethoprim susceptibility in E. coli community-acquired urinary tract infections in France. Médecine Et Maladies Infectieuses, 2018, 48, 410-413.	5.0	7
131	Impacts of Dosing Frequency of the Combination Rifampin-Streptomycin on Its Bactericidal and Sterilizing Activities against <i>Mycobacterium ulcerans</i> in Mice. Antimicrobial Agents and Chemotherapy, 2009, 53, 2955-2959.	3.2	6
132	Multidrugâ€Resistant <i>Acinetobacter baumannii</i> Infections in Three Returning Travelers Evacuated From Algeria, Thailand, and Turkey After Hospitalization in Local Intensive Care Units. Journal of Travel Medicine, 2011, 18, 358-360.	3.0	6
133	Awareness among French healthcare workers of the transmission of multidrug resistant organisms: a large cross-sectional survey. Antimicrobial Resistance and Infection Control, 2019, 8, 173.	4.1	6
134	Low carriage of vancomycin-resistant enterococci in the digestive tract of French hospitalised patients: a nationwide prospective study in 2006. Journal of Hospital Infection, 2011, 77, 179-181.	2.9	5
135	Survey of French physician practices in treatment and control of transmission of smear-positive tuberculosis. International Journal of Tuberculosis and Lung Disease, 2015, 19, 205-209.	1.2	5
136	<i>Erwinia billingiae</i> as Unusual Cause of Septic Arthritis, France, 2017. Emerging Infectious Diseases, 2019, 25, 1587-1589.	4.3	5
137	Ciprofloxacin population pharmacokinetics during long-term treatment of osteoarticular infections. Journal of Antimicrobial Chemotherapy, 2021, 76, 2906-2913.	3.0	5
138	Impact of the revised definition of extensively drug-resistant tuberculosis. European Respiratory Journal, 2021, 58, 2100641.	6.7	5
139	<i>Mycobacterium chimaera</i> Genomics With Regard to Epidemiological and Clinical Investigations Conducted for an Open Chest Postsurgical <i>Mycobacterium chimaera</i> Infection Outbreak. Open Forum Infectious Diseases, 2021, 8, ofab192.	0.9	5
140	Gentamicin-Susceptible or Gentamicin-Resistant Methicillin-Resistant Staphylococcus aureus A Case-Case Study. Infection Control and Hospital Epidemiology, 2006, 27, 879-883.	1.8	4
141	<i>qnrA6</i> genetic environment and quinolone resistance conferred on <i>Proteus mirabilis</i> Journal of Antimicrobial Chemotherapy, 2016, 71, 903-908.	3.0	4
142	Combining bacteriophages and dalbavancin for salvage therapy of complex Staphylococcus aureus extradural empyema. MA©decine Et Maladies Infectieuses, 2020, 50, 458-459.	5.0	4
143	Controlling healthcare-associated transmission of SARS-CoV-2 variant of concern 202012/01 in a large hospital network. Journal of Hospital Infection, 2021, 114, 182-184.	2.9	4
144	Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France. Journal of Infection, 2022, 85, 24-30.	3.3	4

#	Article	IF	CITATIONS
145	Do Contact Precautions Reduce the Incidence of Intensive Care Unit–Acquired Pseudomonas aeruginosa Infections? The DPCPYO (Detection and Contact Precautions for Patients With P.) Tj ETQq1 1 0.78431	, <b>45.18</b> gBT /	Oværlock 10
146	Reexpansion Pulmonary Edema Localized to a Lobe. Chest, 1989, 95, 1170.	0.8	2
147	Evaluation of data quality in a laboratory-based surveillance of <i>M. tuberculosis</i> drug resistance and impact on the prevalence of resistance: France, 2004. Epidemiology and Infection, 2008, 136, 1172-1178.	2.1	2
148	Multidrug-resistant bacteria transmitted through high-density EEG in ICU. Seizure: the Journal of the British Epilepsy Association, 2016, 37, 65-68.	2.0	2
149	Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial. Journal of Antimicrobial Chemotherapy, 2016, 71, 783-793.	3.0	2
150	Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1489-1490.	5.6	2
151	Poor Performance of Rapid Molecular Tests to Define Eligibility for the Shortcourse Multidrug-resistant Tuberculosis Regimen. Clinical Infectious Diseases, 2019, 68, 1410-1411.	5.8	2
152	Sampling strategy for bacteriological diagnosis of intrathoracic tuberculosis. Respiratory Medicine and Research, 2021, 79, 100825.	0.6	2
153	Clinical, epidemiological and therapeutic characteristics of Mycoplasma genitalium infection in a French STI center. Infectious Diseases Now, 2021, , .	1.6	2
154	Validation of the Bacterial Meningitis Score in adults consulting at an emergency department: a retrospective multicentric study. European Journal of Emergency Medicine, 2020, 27, 447-453.	1.1	2
155	Corynebacterium striatum thrombophlebitis: a nosocomial multidrug-resistant disease?. Access Microbiology, 2021, 3, 000307.	0.5	2
156	La multirésistance (MDR) de Mycobacterium tuberculosis aux antibiotiques en France depuis 1992. Médecine Et Maladies Infectieuses, 2003, 33, 183-187.	5.0	1
157	Systematic Microbiological Tests in Kidney Transplantation and Their Value in Predicting Posttransplantation Infection. Transplantation Proceedings, 2009, 41, 666-668.	0.6	1
158	Decrease in the incidence of culture-positive meningitis and cerebral tuberculomas in France from 1990 to 2007. Epidemiology and Infection, 2014, 142, 1510-1516.	2.1	1
159	BédaquilineÂ: de l'in vitro aux essais cliniques d'un nouvel antituberculeux. Journal Des Anti-infectieux, 2015, 17, 60-66.	0.1	1
160	Corrigendum to â€Elaboration of a consensual definition of de-escalation allowing a ranking of β-lactams' [Clin Microbiol Infec 21 (2015) 649.e1–649.e10]. Clinical Microbiology and Infection, 2015, 21, e81.	6.0	1
161	A nationwide survey on involvement of clinical microbiologists in antibiotic stewardship programmes in large French hospitals. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 2235-2241.	2.9	1
162	Rapid Molecular Diagnosis of Tuberculosis and Its Resistance to Rifampicin and Isoniazid with Automated MDR/MTB ELITe MGB® Assay. Antibiotics, 2021, 10, 797.	3.7	1

#	Article	IF	CITATIONS
163	Efficacy of aztreonam with ß-lactamase inhibitors against metallo-carbapenemase-producing Enterobacteria. Infectious Diseases Now, 2021, 51, 639-640.	1.6	0
164	Impact of stewardship strategy on antibiotic use in Clostridoides difficile infection. Infectious Diseases Now, 2021, 51, 499-501.	1.6	0
165	Clostridioides difficile Infection Rates after Ceftolozane–Tazobactam and Ceftazidime–Avibactam Treatment Compared to Carbapenem Treatment: A Retrospective Single-Center Study. Hygiene, 2021, 1, 99-105.	1.7	O
166	Randomised Trial to Compare Clarithromycin (Extended Release)-Rifampicin and Streptomycin-Rifampicin for Early, Limited Lesions of $\langle i \rangle$ M. Ulcerans $\langle i \rangle$ Infection. SSRN Electronic Journal, 0, , .	0.4	0
167	359. Ventilator-associated pneumonia in patients with SARS-CoV-2–associated acute respiratory failure requiring mechanical ventilation: a retrospective cohort study. Open Forum Infectious Diseases, 2020, 7, S249-S250.	0.9	O
168	Title is missing!. , 2020, 14, e0007857.		0
169	Title is missing!. , 2020, 14, e0007857.		O
170	Title is missing!. , 2020, 14, e0007857.		0
171	Title is missing!. , 2020, 14, e0007857.		O
172	Title is missing!. , 2020, 14, e0007857.		0
173	Title is missing!. , 2020, 14, e0007857.		O